Welcome to our dedicated page for Atricure news (Ticker: ATRC), a resource for investors and traders seeking the latest updates and insights on Atricure stock.
AtriCure, Inc. develops surgical and minimally invasive technologies for atrial fibrillation, left atrial appendage management and post-operative pain management. Company updates commonly cover quarterly and annual financial results, U.S. and international revenue trends, product adoption for AtriClip, cryoSPHERE, EnCompass and related device families, and clinical programs tied to Afib treatment and pain-blocking cryoablation.
Its disclosed product portfolio includes the FDA-approved Isolator Synergy Ablation System for persistent Afib, AtriClip Left Atrial Appendage Exclusion System products, Hybrid AF Therapy, and cryoICE cryoSPHERE and cryoXT probes for temporary peripheral nerve ablation.
AtriCure (Nasdaq: ATRC) reported Q1 2026 revenue of $141.2 million, up 14.3% year‑over‑year (12.8% constant currency). U.S. revenue was $116.2 million (+14.9%). Gross margin improved to 77.4%, net income was $0.1 million and adjusted EBITDA was $17.1 million. Management guided full‑year 2026 revenue of $600–$610 million, adjusted EBITDA of $80–$82 million, and adjusted EPS of $0.00–$0.04.
AtriCure (Nasdaq: ATRC) will participate in the 2026 Bank of America Securities Health Care Conference. Management will take part in a fireside chat on Tuesday, May 12, 2026 at 10:00 a.m. Pacific Daylight Time. A live audio webcast will be available via the company’s Investors website.
AtriCure (Nasdaq: ATRC) will release its first quarter 2026 financial results on Tuesday, May 5, 2026 and host an audio webcast at 4:30 p.m. ET.
Investors can register to join the live conference call and a live replay will be available at the company's investor events page.
AtriCure (Nasdaq: ATRC) will participate in the Citizens Life Sciences Conference with management appearing in a fireside chat on Tuesday, March 10, 2026 at 1:05 p.m. ET. Interested parties can access a live audio webcast via the company’s Investors web page at https://ir.atricure.com.
AtriCure (Nasdaq: ATRC) reported Q4 2025 revenue $140.5M (+13.1% YoY) and Q4 net income $1.8M with adjusted EBITDA $19.9M. For full year 2025, revenue was $534.5M (+14.9% YoY) and adjusted EBITDA was $61.8M, with a net loss of $11.4M.
Management guided 2026 revenue of $600M–$610M, adjusted EBITDA of $80M–$82M, and projected positive net income and continued cash generation.
AtriCure (Nasdaq: ATRC) will release its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026. The company will host an audio webcast to discuss results at 4:30 p.m. Eastern Time the same day. Investors are asked to register online and to join more than 15 minutes before the call. A live webcast and a replay will be available at the company's investor events page.
AtriCure (Nasdaq: ATRC) reported preliminary, unaudited Q4 2025 revenue of $140.5M (+13% YoY; +12% constant currency) and full-year 2025 revenue of $534.5M (+15% YoY; +14% constant currency). Q4 U.S. revenue was $114.3M and international was $26.2M. Management expects full-year 2025 adjusted EBITDA of $57M–$59M and adjusted loss per share of $0.18–$0.21. Cash and investments totaled about $167M at year-end. For 2026 the company projects revenue of $600M–$610M (+12%–14%), positive adjusted EBITDA of $80M–$82M, net income, and continued positive cash flow.
AtriCure (NASDAQ: ATRC) will participate in the J.P. Morgan 44th Annual Healthcare Conference and present on Wednesday, January 14, 2026 at 10:30 a.m. Pacific Standard Time.
Management presentation will be accessible by a live audio webcast via the company’s Investors website. The presentation covers recent corporate developments in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management.
AtriCure (Nasdaq: ATRC) announced first‑in‑human treatments using a novel dual energy platform that combines Pulsed Field Ablation (PFA) with Advanced Radiofrequency Ablation (Advanced RFA) with the EnCompass clamp on December 11, 2025. In the first two patients, total procedural ablation time to create a box lesion isolating pulmonary veins and left atrial posterior wall was less than 60 seconds, with each ablation showing acute electrical isolation.
The company says the system can use RFA, PFA, or both, builds on AtriCure’s Isolator Synergy history (> 450,000 patients treated; > 100 publications), and expects to initiate a clinical trial in the coming year. Advanced RFA and PFA are not yet approved in any market.
AtriCure (Nasdaq: ATRC) will participate in the Piper Sandler 37th Annual Healthcare Conference. Management is scheduled for a fireside discussion on Tuesday, December 2, 2025 at 10:00 a.m. ET. Interested parties may access a live audio webcast via the company's Investors website.
The presentation focuses on company developments in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management.